Ampomah Patrick Baah, Kong Wan Ting, Zharkova Olga, Chua Sonja C J H, Perumal Samy R, Lim Lina H K
Department of Physiology, NUS Immunology Program, Centre for Life Sciences, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Front Pharmacol. 2018 Nov 15;9:1282. doi: 10.3389/fphar.2018.01282. eCollection 2018.
Influenza A viruses (IAVs) are important human respiratory pathogens which cause seasonal or periodic endemic infections. IAV can result in severe or fatal clinical complications including pneumonia and respiratory distress syndrome. Treatment of IAV infections is complicated because the virus can evade host immunity through antigenic drifts and antigenic shifts, to establish infections making new treatment options desirable. Annexins (ANXs) are a family of calcium and phospholipid binding proteins with immunomodulatory roles in viral infections, lung injury, and inflammation. A current understanding of the role of ANXs in modulating IAV infection and host responses will enable the future development of more effective antiviral therapies. This review presents a comprehensive understanding of the advances made in the field of ANXs, in particular, ANXA1 and IAV research and highlights the importance of ANXs as a suitable target for IAV therapy.
甲型流感病毒(IAV)是重要的人类呼吸道病原体,可引起季节性或周期性的地方性感染。IAV可导致包括肺炎和呼吸窘迫综合征在内的严重或致命临床并发症。IAV感染的治疗较为复杂,因为该病毒可通过抗原漂移和抗原转换逃避宿主免疫,从而引发感染,因此需要新的治疗选择。膜联蛋白(ANX)是一类钙和磷脂结合蛋白家族,在病毒感染、肺损伤和炎症中具有免疫调节作用。当前对ANX在调节IAV感染和宿主反应中作用的理解将有助于未来开发更有效的抗病毒疗法。本综述全面介绍了ANX领域,特别是膜联蛋白A1(ANXA1)与IAV研究取得的进展,并强调了ANX作为IAV治疗合适靶点的重要性。